{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-016779","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.446407+00:00","generated_at":"2026-05-26T04:59:03.685162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027","bullets":["Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.","NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.","Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.","NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-016779","json":"https://secwatch.observer/filing/0001104659-25-016779.json","markdown":"https://secwatch.observer/filing/0001104659-25-016779.md","text":"https://secwatch.observer/filing/0001104659-25-016779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/0001104659-25-016779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/tm257439d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:59:03.685162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}